NCT01778088View on ClinicalTrials.gov

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

January 31, 2015

Conditions
Glioma
Interventions
DRUG

I-131-CLR1404 Injection

Trial Locations (1)

21201

University of Maryland School of Medicine, Baltimore

Sponsors
All Listed Sponsors
lead

Cellectar Biosciences, Inc.

INDUSTRY